Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGCD290 and fluconazole for moderate to severe vulvovaginal candidiasis
NCT01497223Phase 2Completed
- Sponsor
- MethylGene Inc.
- Start
- Dec 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MGCD290 in vulvovaginal candidiasis (VVC), sponsored by MethylGene Inc.. Started Dec 2011; status: completed.
02
Drugs
MGCD290
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT01497223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01497223.